155 related articles for article (PubMed ID: 25794775)
1. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.
Abduljabbar R; Al-Kaabi MM; Negm OH; Jerjees D; Muftah AA; Mukherjee A; Lai CF; Buluwela L; Ali S; Tighe PJ; Green A; Ellis I; Rakha E
Breast Cancer Res Treat; 2015 Apr; 150(3):511-22. PubMed ID: 25794775
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
3. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions.
Suzuki T; Hayashi S; Miki Y; Nakamura Y; Moriya T; Sugawara A; Ishida T; Ohuchi N; Sasano H
Endocr Relat Cancer; 2006 Mar; 13(1):233-50. PubMed ID: 16601291
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterisation of breast cancer: the role of CDC42.
Chrysanthou E; Gorringe KL; Joseph C; Craze M; Nolan CC; Diez-Rodriguez M; Green AR; Rakha EA; Ellis IO; Mukherjee A
Breast Cancer Res Treat; 2017 Jul; 164(2):317-325. PubMed ID: 28451966
[TBL] [Abstract][Full Text] [Related]
6. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
Joseph C; Al-Izzi S; Alsaleem M; Kurozumi S; Toss MS; Arshad M; Goh FQ; Alshankyty IM; Aleskandarany MA; Ali S; Ellis IO; Mongan NP; Green AR; Rakha EA
Br J Cancer; 2019 Oct; 121(9):776-785. PubMed ID: 31558802
[TBL] [Abstract][Full Text] [Related]
7. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.
Jerjees DA; Alabdullah M; Alkaabi M; Abduljabbar R; Muftah A; Nolan C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Aug; 147(1):25-37. PubMed ID: 25085753
[TBL] [Abstract][Full Text] [Related]
8. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
[TBL] [Abstract][Full Text] [Related]
9. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
10. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.
Habashy HO; Rakha EA; Aleskandarany M; Ahmed MA; Green AR; Ellis IO; Powe DG
Breast Cancer Res Treat; 2011 Aug; 129(1):11-21. PubMed ID: 21336599
[TBL] [Abstract][Full Text] [Related]
11. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer.
Althobiti M; El-Sharawy KA; Joseph C; Aleskandarany M; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2021 Oct; 189(3):621-630. PubMed ID: 34453638
[TBL] [Abstract][Full Text] [Related]
14. DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.
Powe DG; Dhondalay GK; Lemetre C; Allen T; Habashy HO; Ellis IO; Rees R; Ball GR
PLoS One; 2014; 9(1):e84428. PubMed ID: 24392136
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.
Habashy HO; Powe DG; Rakha EA; Ball G; Macmillan RD; Green AR; Ellis IO
Breast Cancer Res Treat; 2010 Apr; 120(3):603-12. PubMed ID: 19495959
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
18. High nuclear MSK1 is associated with longer survival in breast cancer patients.
Pu X; Storr SJ; Ahmad NS; Rakha EA; Green AR; Ellis IO; Martin SG
J Cancer Res Clin Oncol; 2018 Mar; 144(3):509-517. PubMed ID: 29327245
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
20. PPARgamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations.
Jiang Y; Zou L; Zhang C; He S; Cheng C; Xu J; Lu W; Zhang Y; Zhang H; Wang D; Shen A
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1551-9. PubMed ID: 19495794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
